Table 2.
Characteristics of eligible studies from RNA-seq data and microarray profiles
| Study | Cancer type | Group | Number | HR |
|---|---|---|---|---|
| TCGA BLCA | Urothelial bladder cancer | Urinary system | 404 | 0.800 (0.595–1.074) |
| TCGA BRCA | Breast invasive cancer | Endocrine system | 988 | 0.793 (0.562–1.119) |
| TCGA CESC | Cervical cancer | Reproductive system | 266 | 0.736 (0.444–1.220) |
| TCGA COAD | Colon adenocarcinoma | Digestive system | 426 | 0.834 (0.559–1.245) |
| TCGA ESCA | Esophageal cancer | Digestive system | 144 | 0.869 (0.517–1.460) |
| TCGA GBM | Glioblastoma multiforme | Nervous system | 562 | 1.075 (0.896–1.290) |
| TCGA HNSC | Head and neck squamous cell carcinoma | Other | 500 | 0.800 (0.611–1.048) |
| TCGA KIRC | Kidney renal clear cell carcinoma | Urinary system | 506 | 1.177 (0.871–1.592) |
| TCGA KIRP | Kidney renal papillary cell carcinoma | Urinary system | 286 | 0.805 (0.442–1.468) |
| TCGA LAML | Acute myeloid leukemia | Other | 164 | 0.596 (0.400–0.890) |
| TCGA LGG | Lower grade glioma | Nervous system | 506 | 1.101 (0.773–1.569) |
| TCGA LIHC | Liver hepatocellular carcinoma | Digestive system | 262 | 1.102 (0.775–1.567) |
| TCGA LUAD | Lung adenocarcinoma | Respiratory system | 262 | 0.743 (0.552–1.000) |
| TCGA LUSC | Lung squamous cell carcinoma | Respiratory system | 466 | 0.815 (0.615–1.079) |
| TCGA OV | Ovarian serous cystadenocarcinoma | Reproductive system | 470 | 0.855 (0.680–1.075) |
| TCGA PAAD | Pancreatic adenocarcinoma | Digestive system | 174 | 0.776 (0.509–1.181) |
| TCGA READ | Rectum adenocarcinoma | Digestive system | 154 | 0.765 (0.348–1.680) |
| TCGA SARC | Sarcoma | Other | 258 | 1.031 (0.691–1.539) |
| TCGA SKCM | Skin Cutaneous Melanoma | Other | 438 | 1.113 (0.845–1.467) |
| TCGA STAD | Stomach adenocarcinoma | Digestive system | 400 | 0.790 (0.579–1.078) |
| TCGA UCEC | Uterine corpus endometrial carcinoma | Reproductive system | 534 | 0.608 (0.396–0.932) |
| GSE10694 | Liver hepatocellular carcinoma | Digestive system | 156 | 0.900 (0.620–1.310) |
| GSE13937 | Lung cancer | Respiratory system | 152 | 1.360 (0.830–2.220) |
| GSE16025 | Lung cancer | Respiratory system | 61 | 0.620 (0.310–1.220) |
| GSE21849 | Acute myeloid leukemia | Other | 37 | 0.340 (0.070–1.750) |
| GSE27290 | Ovarian serous cystadenocarcinoma | Reproductive system | 62 | 0.870 (0.460–1.640) |
| GSE27705 | Lung cancer | Respiratory system | 20 | 0.250 (0.070–0.960) |
| GSE31384 | Liver hepatocellular carcinoma | Digestive system | 166 | 1.410 (0.890–2.250) |
| GSE36682 | Nasopharyngeal carcinoma | Respiratory system | 62 | 1.030 (0.450–2.380) |
| GSE37405-GPL13703 | Breast invasive cancer | Endocrine system | 60 | 1.560 (0.740–3.330) |
| GSE37405-GPL14149 | Breast invasive cancer | Endocrine system | 40 | 0.800 (0.300–2.130) |